Late Toxicity after Single Dose HDR Prostate Brachytherapy and EBRT for Localized Prostate Cancer: Clinical and Dosimetric Predictors in a Prospective Cohort Study

      Over the last decades several randomized and observational studies have reported a significant improvement in biochemical control favouring combined treatments over EBRT alone. Nonetheless, prostate brachytherapy is still performed only in highly specialised centres and EBRT is still widely considered the standard of care in radiotherapy for prostate cancer. This might be partly explained by the toxicity profile reported in the aforementioned studies. The objective of this study is to describe the genitourinary (GU) and gastrointestinal (GI) late toxicity profile and to analyse the clinical and dosimetric predictive factors in a prospective trial of combination of EBRT and high-dose-rate (HDR) prostate brachytherapy (BT) for prostate cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect